FREE FEDEX 2-DAY SHIPPING OVER $200Same-Day Dispatch Before 1 PM ETThird-Party TestedBatch COAs Available
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
Peptide Pilots
Log in
Melanocortin systemReceptor selectivitySafety literature

Melanocortin Receptor Peptides: How the PT-141 and Melanotan II Literature Differs

Both peptides derive from the same melanocortin family, but one carries a completed regulatory trial programme and the other is defined mainly by case-report literature. Selectivity explains much of the gap.

By Patrick Ergu, MSc, Molecular Pharmacology8 min read

This article summarises published scientific literature for laboratory professionals. It is not medical advice and does not describe human or veterinary use. All materials supplied by Peptide Pilots are for controlled laboratory research only.

Key takeaways

  • The melanocortin system has five receptor subtypes, and the peptides studied in this space are only partially selective between them.
  • PT-141 and Melanotan II have very different evidence bases, one clinical-stage and one largely case-report driven.
  • Reported adverse signals in this class are mechanistically plausible rather than incidental, and should be read as part of the pharmacology.

Five receptors, uneven selectivity

The melanocortin system comprises five G protein-coupled receptors with distinct tissue distributions: MC1R in melanocytes, MC2R in the adrenal cortex, MC3R and MC4R in the central nervous system, and MC5R in exocrine tissue. A peptide's behaviour in a study is largely a function of which of these it engages and at what relative potency. Bremelanotide (PT-141) is described as acting preferentially at MC4R and MC3R; Melanotan II is a broadly non-selective agonist across MC1R, MC3R, MC4R and MC5R.

That difference in selectivity is the single most useful lens for reading their respective literatures, because non-selective agonism produces effects across pigmentation, central and exocrine pathways simultaneously.

What each evidence base consists of

  • PT-141 / bremelanotide: registered, placebo-controlled trials with prespecified patient-reported endpoints, published adverse-event tables and a documented regulatory review record.
  • Melanotan II: early pharmacology studies plus a substantial dermatology and toxicology case-report literature, including reports of pigmented lesion change, nausea and systemic effects.

Case reports are not a weaker version of trials; they answer a different question. They are good at surfacing rare and unexpected events and poor at estimating frequency. A literature made mostly of case reports tells you what can happen, not how often.

Reading safety signals honestly

Where documented safety signals exist, the neutral presentation is to state them plainly with citations, rather than to omit them or to imply they generalise beyond what was reported. Pigmentation-related observations for non-selective melanocortin agonists are well documented in dermatology journals and belong in any accurate summary of that compound.

Compound pages

Both compounds have full research library entries with identifiers, receptor pharmacology, separated evidence tiers, study tables and explicit limitations.

Related research

References

  1. Kingsberg, S. A., et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology. View source
  2. Cone, R. D. (2006). Studies on the physiological functions of the melanocortin system. Endocrine Reviews. View source
  3. Langan, E. A., et al. (2010). Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'?. British Journal of Dermatology. View source

Frequently asked questions

No. PT-141 (bremelanotide) is a metabolite-related analogue derived from the Melanotan II programme, and the two share a melanocortin-receptor mechanism, but they are distinct molecules with different receptor selectivity profiles and very different evidence bases. Confusing the two is a common source of error in secondary summaries of this literature.

The melanocortin family has five receptor subtypes (MC1R–MC5R) with distinct tissue distributions. Melanotan II is a non-selective agonist active at several subtypes including MC1R and MC4R, while bremelanotide's published pharmacology is characterised primarily in terms of MC4R activity. Receptor selectivity is central to interpreting the divergent study findings.

Yes — bremelanotide has been evaluated in randomised phase 3 trials, which makes its literature qualitatively different from most research peptides discussed on this site. Melanotan II, by contrast, lacks a comparable controlled-trial base. This asymmetry is exactly why the two compounds' literatures must be read separately. Any material supplied by Peptide Pilots is for laboratory research only, regardless of what the clinical literature describes.